Moby summary of Altimmune, Inc.'s Q4 2025 earnings call ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label risks keep it Hold—read now.

Industry analysts say the arrival of these affordable alternatives—expected to be priced at one-third to one-fifth of the innovator's cost.

Frequent late-night hunger may reflect hormonal shifts, sleep disruption or metabolic conditions rather than poor ...

Conference Call Participants. Lee Roth - Burns McClellan, Inc. Jiale Song - Jefferies LLC, Research Division Jasmine Fels - Barclays Bank PLC, Research Division Dominic Lorenzi - ...

Omada Health (NASDAQ:OMDA) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by. Welcome to the Omada Health Fourth Quarter 2025 Earnings Conference Call.

Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...

A home blood pressure telemonitoring (HBPT) program effectively reduced BP in real-world clinical settings, but its enrollment expenses increased overall costs. The HBPT program reduced BP clinic ...